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We have recently developed an HIV-1 packaging cell line, C422, as an improved tool for anti-HIV gene therapy. After stable
transfection with an HIV-1 or HIV-2 vector, C422 has been shown to synthesize virions able to transduce CD41 T cells and
macrophages. We now report that HIV vectors per se, in the absence of antiviral genes, inhibit HIV infection of transduced
cells. This antiviral effect was shown to be due, at least in part, to a TAR and RRE decoy effect. These data highlight further
advantages of HIV-derived gene delivery systems for HIV therapy, in addition to CD4 cell targeting and the ability to transduce
nondividing cells. © 1998 Academic Press
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INTRODUCTION
In our efforts to develop gene therapy for HIV infection
(Yu et al., 1994), we have recently established a stable
system of gene transfer based on an HIV-1 packaging
cell line and HIV vectors (Poeschla et al., 1996; Corbeau
et al., 1996, 1997). We have previously shown that these
vectors were able to specifically deliver genes into CD41
T cells and nondividing cells such as terminally differen-
tiated macrophages (Corbeau et al., 1996, 1997). Delivery
of a therapeutic gene in an HIV virion core should ensure
its entry through the same cell compartments as the
virus target and thus increase its efficiency. Further ad-
vantages can be envisioned: (i) the expression of genes
from the vector LTR may be specifically induced upon
HIV infection through tat regulation; (ii) components of
the vector RNA may have intrinsic RNA decoy effects at
the transcriptional and mRNA processing levels; and (iii)
vector RNA can compete with genomic RNA for dimer-
ization and packaging and thus can be mobilized to other
target cells. In this paper, we present evidences for a
TAR and RRE3 decoy effect on wild-type tat and/or rev in
cells stably transduced with a minimal HIV vector with no
therapeutic genes inserted, as well as a reduction of
virus infection in these transduced cells.
RESULTS
Transduction of CD41 cells with a minimal
HIV-1 vector
We constructed a minimal vector, V0gpt (Fig. 1A).
V0gpt contains only the two HIV-1 LTRs, the packaging
sequences, C, located 59 of the ATG gag initiator, i.e., the
three first loops of the main packaging signal (Clever et
al., 1995; Mc Bride and Panganiban, 1996), and the SL3-
gpt cassette. We stably transfected V0gpt into our HIV
packaging cell line, C422. The supernatant of the stable
cell lines (four gV0 lines A, B, C, and D were indepen-
dently derived) were checked for infectivity and for trans-
ducing capacity. The virions produced by these cell lines
were noninfectious. Ten nanograms of p24 equivalent of
gV0 virions did not induce any viral production after a
4-week culture in the presence of Molt4/8 CD41 cells. In
the same assay, wild-type HIV-1-MN tissue culture infec-
tious dose 50% (TCID50) was 1023 ng (Table 1). Yet, gV0
virions were able to transduce HeLa-T4 cells—and not
HeLa cells—with a titer ranging from 1.2 to 2.0 3 103
transducing units (TU) per milliliter of supernatant (Table
1). The integrity of the vector in gene altered cells was
confirmed by Southern blot (data not shown). Of note, the
transduction efficiencies we obtained here with V0gpt
are lower than those (1.0 3104 to 1.4 3 105 TU/ml)
obtained in our previous work with a more complex
vector, V653gpt (Fig. 1A) (Corbeau et al., 1996, 1997). This
result confirms the requirement for sequences in addi-
tion to C for optimal packaging (Parolin et al., 1994).
Anti-tat effect of the V0gpt vector
To evidence a TAR decoy effect of V0gpt on tat, we
cotransfected the reporter plasmid pLTR-CAT and a tat
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expression vector, pTAT, into V0gpt-transduced cells and
nontransduced HeLa-T4 cells. In three independent ex-
periments, the amount of CAT protein produced by
V0gpt-transduced cells under tat transactivation was re-
producibly reduced (Fig. 2A). As a control, the same pair
of cells was transfected with pCMV-CAT in parallel, and
the production of CAT was the same in cells with or
without vector transduction (Fig. 2B).
We next wanted to measure the consequence of this
vector TAR decoy effect on HIV expression. HeLa-T4
cells transduced with V0gpt and control cells were trans-
fected with two different input concentrations of a wild-
type HIV-1-MN clone DNA, and viral production was
monitored (Fig. 3). At both MN DNA inputs, a reduction in
p24 expression was observed in Vogpt-transduced cells
compared with nontransduced cells. This inhibition must
be due in part to the TAR decoy effect.
Anti-rev effect of the V653gpt vector
We have previously used an HIV-1 vector V653gpt
(Fig. 1A) to transduce CD41 cells. In addition to the
two HIV LTRs and an SL3-gpt cassette, V653gpt con-
tains three sequences involved in optimal packaging:
the major C sequence, a 59 portion of the gag gene,
and a fragment of the envgene fragment containing
RRE. Therefore, we hypothesized that during wild-type
HIV infection of a V653gpt-transduced cell, the vector
RRE sequence might also have a decoy effect on
newly synthesized rev proteins. To test this possibility,
we carried out a functional assay using a reporter
plasmid, pDM128, which contains RRE and the CAT
gene in an intron (Hope et al., 1990). (Fig. 1B). In the
absence of rev, cells transfected with pDM128 express
only cytoplasmic spliced transcripts and do not pro-
duce CAT protein. In the presence of rev, unspliced
RNAs enter the cytoplasm, and CAT is synthesized. We
FIG. 1. Structure of the plasmids used in this study: HIV vectors (A) and plasmids for CAT assays (B). SD, splice donor; SA, splice acceptor.
TABLE 1
Infectivity and Transduction Capacity of gv0 Cell Lines
Cell supernatant
Infectivitya
(TCID50/10 ng
p24 equivalent)
Transduction
efficiencyb
(transducing units/ml)
gV0A 0 1.6 3 103
gV0B 0 1.4 3 103
gV0C 0 1.2 3 103
gV0D 0 2.0 3 103
Wild-type HIV-1-MN 104 Not applicable
a Infectivity was measured in Molt4/8 cells after a month culture by
p24 antigen capture assay.
b Transduction efficiency was evaluated on HeLa-T4 cells as previ-
ously described (Corbeau et al., 1996).
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compared the amount of CAT produced by V653gpt-
transduced cells or control cells after cotransfection
with the reporter gene, pDM128, and a plasmid encod-
ing rev, pREV (Fig. 1B). In addition, the cells were
transfected with the tat expression plasmid, pTAT (Fig.
1B), to induce the expression of RRE1 V653gpt tran-
scripts. As shown in Fig. 4A, the rev-dependent pro-
duction of CAT was reduced in V653gpt-transduced
cells. In contrast, CAT expression from a CMV pro-
moter was not affected when pCMV-CAT was used for
transfection, ruling out any constitutive defect of the
V653gpt-transduced cells (Fig. 4B). Thus, V653gpt
should interfere with the rev–RRE interaction neces-
sary for viral structural protein expression during HIV
infection.
DISCUSSION
Lentiviral vectors have recently received much atten-
tion because of their ability to mediate stable gene trans-
fer in nondividing cells. We have shown previously that
HIV-1 and HIV-2 vectors produced from a stable HIV-1
FIG. 2. TAR decoy effect of the HIV vector V0gpt on tat-induced LTR activation. (A) HeLa-T4 cells, either transduced or not with V0gpt, were
cotransfected with the tat encoding plasmid pTAT and the reporter plasmid pLTR-CAT. The CAT/protein concentrations ratio was determined on cell
lysates at day 3. (B) As a positive control, the same cells were transfected with pCMV-CAT and analyzed for CAT production at day 3.
FIG. 3. Effect of V0gpt transduction on HIV expression. V0gpt transduced HeLa-T4 cells (n) or control Hela-T4 cells (F) were transfected with 2
mg/ml (A) or 4 mg/ml (B) of the molecular clone HIV-1-MN. Viral production was monitored for 2 days by measuring p24 concentration in cell culture
supernatant.
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packaging system were able to transduce specifically
CD41 cells, including primary human macrophages. Al-
though HIV-based vectors can be potentially applied to a
variety of disease models, the first likely test case will be
in HIV-infected patients from a safety perspective. One
can also readily argue for additional advantages for us-
ing such vectors to deliver anti-HIV genes in the context
of the replication cycle of HIV (Fig. 5). With the native
envelope protein, the vector would retain the exquisite
target cell tropism for CD41 cells. Once it gains entry into
the cell, the presence of Vpr, matrix protein, and the viral
integrase will facilitate nuclear import of the preintegra-
tion complex in the absence of cell division. At the
transcriptional level, we showed in this study that the
TAR element in the LTR exerts a decoy effect on tat
transactivation. Such a TAR decoy effect has already
been reported in other systems (Sullenger et al., 1990;
Lisziewicz et al., 1993); Graham and Maio, 1990). For
instance, Sullenger et al. (1990) obtained a 99% inhibition
of HIV-1 replication in CEM cells transduced with a
double copy murine retroviral vector containing a tRNA-
TAR transcription unit. It is possible that, in addition to a
TAR decoy effect, the vector LTR may also have a decoy
effect on other viral transcription activators, i.e., the con-
stitutive and inducible cellular DNA-binding proteins in-
volved in HIV activation (Gaynor, 1992).
At the posttranscriptional level, we also observed an
RRE decoy effect using an HIV vector that is optimal for
packaging. Our results were comparable to those of Lee
et al. (1994), which showed a 70–83% inhibition of rev
function in CEM cells transduced with a minimal RRE
decoy driven by a tRNA promoter. Bevec et al. also
showed that CEM cells transduced with a murine retro-
viral vector harboring complete copies of RRE driven by
the vector LTR were partially resistant to HIV infection
(Bevec et al., 1994). It is noteworthy that in our system,
the RRE decoy expression is inducible, so that no toxic
effect due to the sequestration of RRE-binding cellular
factors (Shukla et al., 1994; Vaishnav et al., 1991) should
be observed. Furthermore, the presence of RRE should
direct the vector through the rev-RRE export pathway
utilized by HIV RNA from the nucleus to the cytoplasm
(Meyer and Malim, 1994; Luznik et al., 1995). Such co-
trafficking with viral RNA would be an advantage for a
vector carrying an antiviral ribozyme (Sullenger and
Cech, 1993). V653gpt, which contains a 59-fragment of
the gag gene, could encode for a trans-dominant gag
protein (Trono et al., 1989). However, the presence of gag
FIG. 4. RRE decoy effect of the HIV-1 vector V653gpt on rev. (A) HeLa-T4 cells, either transduced or not with V653gpt, were cotransfected with three
plasmids: the tat and rev expression plasmids pTAT and pREV, respectively, and the rev-dependent reporter plasmid pDM128. Three days
posttransfection, the CAT/protein concentrations ratio was determined on cell lysates by CAT ELISA and Bradford protein assay. (B) As a positive
control, the same cells were transfected with pCMV-CAT and analyzed for CAT production at day 3.
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coding sequences could be a disadvantage in vivo:
V653gpt-transduced cells expressing gag proteins might
be eliminated by the immune system. Therefore, it may
be preferable to introduce mutations at the ATG site to
eliminate Gag expression.
A final advantage of HIV vectors pertains to the steps
of viral genomic RNA dimerization and packaging (Fig. 5).
All HIV vectors contain, upstream of the 59 splice donor
site, a region named dimer linkage structure (DLS) in-
volved in the dimerization of the two HIV RNA strands
(Darlix et al., 1990; Marquet et al., 1991). In particular, the
first loop of the main packaging signal is able to induce
the formation of homo- or heterodimers through a ‘‘kiss-
ing-loop’’ interaction (Paillard et al., 1996; Clever et al.,
1996). Therefore, it may be postulated that HIV vector
RNA could dimerize with HIV genomic RNA so that vec-
tor/genomic RNA heterodimers could be encapsidated in
budding particles. Such hybrid virions might not be in-
fectious because of a block in the strand transfers during
reverse transcription and/or as a result of the production
of defective recombinants. Thus, the vector DLS could
interfere with the replicative cycle of HIV in transduced
cells. Moreover, by interacting with the HIV genomic RNA
DLS, the vector DLS could colocalize both RNAs. This
colocalization should improve the cleavage efficiency of
the viral RNA by an anti-HIV ribozyme inserted in the
vector, as suggested by Sullenger and Cech ( 1993). All
HIV vectors also contain the main packaging signal C
(Lever et al., 1989; Aldovini and Young, 1990; Clavel and
Orenstein, 1990; Poznansky et al., 1991; Hayashi et al.,
1992). Therefore, they may compete with wild-type HIV
genomic RNA for packaging into progeny virions during
productive infection of transduced cells. Dropulic and
Jeang (1994) reported such a competition for packaging
using HIV vectors containing a hammerhead ribozyme.
Their system was a transient cotransfection of Jurkat
cells with a wild-type HIV molecular clone and vector.
With this protocol, they observed a delay in the produc-
tion of virions which exclusively contained vector RNA
and no wild-type HIV RNA, whereas genomic HIV RNA
was detectable intracellularly. This means that competi-
tion between vector RNA and genomic viral RNA for
packaging may occur at a certain intracellular ratio of
vector/genomic HIV RNA, particularly if the vector carries
an antiviral ribozyme. Thus, during infection of trans-
duced cells, newly synthesized viral particles could
package vector RNA. In this way, the vector can be
mobilized and disseminated to naive target cells. In vivo,
this might be a major advantage for an HIV-derived
system of gene transfer.
FIG. 5. Theoretical advantages of an HIV-derived gene delivery system in the context of the HIV replication cycle. Closed boxes represent vector
LTRs, and open boxes represent wild-type LTRs.
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MATERIALS AND METHODS
Vectors
The vector V0gpt (Fig. 1A) was generated from the
V0SN plasmid (Parolin et al., 1994) by replacing the
neomycin phosphotransferase (neoR) gene with the
xanthine-guanine phosphoribosyl transferase (gpt) gene.
The gpt gene was amplified by PCR introducing XhoI and
SalI sites at the 59 and 39 ends of the PCR product,
respectively, using the oligomers 59CCGCTCGAGAT-
GAGCGAAAAATACATCGTC; and 39CGGTCGACTTAGCG-
GCC GCGACCGGAGATTGGCGGG. V0SN was deleted of
a SalI–SalI fragment containing the neoR gene and li-
gated with the PCR product digested with XhoI and SalI.
V653gpt has been described elsewhere (Corbeau et al.,
1996, 1997). The V0gpt vector was stably transfected into
the HIV-1 packaging cell line C422, which was obtained
by stably transfecting HeLa cells with an HIV-1-MN clone
deleted in the major packaging signal (Corbeau et al.,
1996, 1997). Stable vector producing cells were selected
with mycophenolic acid, and their supernatant was used
to transduce HeLa-T4 cells as previously described (Cor-
beau et al., 1996, 1997). Four independent cell lines
which stably produce the packaged vector, gV0A, B, C,
and D, were derived.
Plasmids used in CAT assays
As shown in figure 1, pLTR-CAT and pCMV-CAT plas-
mids contain the chloramphenicol acetyltransferase
(CAT) reporter gene driven by the HIV-1 LTR and a cyto-
megalovirus (CMV) promoter, respectively. In pTAT, the
tat gene is driven by an HIV-1 LTR (Knight and Flomerfelt,
1987). pREV contains the CMV promoter, and the rev
gene from HIV-1-BRU (Hope et al., 1990). pDM128, de-
rived from the env region of HIV-1 by Hope et al. (1990),
contains the Simian Virus 40 promoter, the CAT gene,
and a fragment of HIV-1 env including RRE, in both an
intron flanked by HIV-1 splice donor and acceptor sites.
CAT assays
Plasmids were transfected by electroporation at 12, 6, 12,
12, and 6 mg/ml for pLTR-CAT, pTAT, pCMV-CAT, pDM128,
and pREV, respectively. Four million HeLa-T4 cells in 400 ml
of 20% RPMI 1640 were mixed at 4°C with the plasmids.
After 10 min on ice, cells were electroporated at 250 V and
cultured in T25 flasks (Costar) containing 8 ml of DMEM–
10% FCS. At day 3 postelectroporation, CAT production was
determined by immunocapture on the cell lysate (CAT
ELISA, Boehringer Mannheim, Indianapolis, IN). To deter-
mine the protein concentration, 8 ml of each cell lysate was
mixed in a microtiter plate with 152 ml of water and 40 ml of
Bradford protein assay dye reagent concentrate (Bio-Rad,
Hercules, CA), and the absorbance was read at 570 nm. A
standard curve was established using bovine immuno-
globulins.
Cell transfection with HIV-1-MN
Cells were electroporated as described in the CAT
assay, and the p24 production was monitored in the
culture supernatant using an antigen capture assay
(Coulter). The HIV-1-MN molecular clone has been de-
scribed previously (Corbeau et al., 1996, 1997).
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